Santhera Pharmaceuticals Ownership
| SPHDF Stock | USD 9.42 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Santhera |
Santhera Pink Sheet Ownership Analysis
About 19.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.68. Santhera Pharmaceuticals had not issued any dividends in recent years. Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland. SANTHERA PHARMACEUTICALS operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs people.The quote for Santhera Pharmaceuticals Holding is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Santhera Pharmaceuticals Holding contact Thomas Meier at 41 61 906 89 50 or learn more at https://www.santhera.com.Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Santhera Pink Sheet
Santhera Pharmaceuticals financial ratios help investors to determine whether Santhera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santhera with respect to the benefits of owning Santhera Pharmaceuticals security.